icon-folder.gif   Conference Reports for NATAP  
 
  IDWeek
October 3 -7, 2018
San Francisco, CA
Back grey_arrow_rt.gif
 
 
 
Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1
 
 
  Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco
 
Joseph J. Eron1, Chloe Orkin2, Douglas Cunningham3, Federico Pulido4, Frank A. Post5, Stéphane De Wit6, Erkki Lathouwers7, Veerle Hufkens7, Romana Petrovic7, Erika Van Landuyt7, on behalf of the EMERALD study group
 
1The University of North Carolina School of Medicine, Chapel Hill, NC; 2Department of Infection and Immunity, Royal London Hospital and Queen Mary University, Barts Health NHS Trust, London, UK; 3Pueblo Family Physicians, Phoenix, AZ, USA; 4HIV Unit, Hospital 12 de Octubre, imas12, UCM, Madrid, Spain; 5King's College Hospital NHS Foundation Trust, London, United Kingdom; 6Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium; 7Janssen Pharmaceutica NV, Beerse, Belgium

1010181

1010182

1010183

1010184

1010185

1010186

1010187

1010188